| Focus: | To revolutionize health care by focusing on all areas related to the development of molecular imaging probes - chemical compounds that provide a non-invasive means to diagnose disease at its earliest stage. |
| Funding: | $28,755,575 for entire funding period |
| Scientific Director and CEO: | Dr. John Valliant |
| Web site: |
April 23
CPDC Cancer Imaging Research Programs Receive Renewed Funding of $2.9 Million from OICR
January 30
Radiopharmaceutical for Targeted Treatment of Prostate Cancer to Enter Clinical Trials